Author: Zacks Small Cap Research

12346220 / 619 POSTS
By Steven Ralston, CFATSX:BHT.V | OTC:RIINF READ THE FULL BHT.V RESEARCH REPORT Braveheart Resources Inc. (TSX:BHT.V) (OTC:RIINF) is a Canadian-based junior mining company focused on the exploration and development of proven, past-producing mines in ...
By John VandermostenTSX:RVX.TO During Resverlogix’ (TSX:RVX.TO) Annual Meeting of Shareholders on October 31st, the company shared milestones expected over the next few months. Key events include further consultation with the FDA and presentation of ...
NASDAQ:INO Addressing cancer with immuno-oncology (IO) has become one of the most exciting areas in biotechnology over the last decade. With the first approval of checkpoint inhibitors beginning in 2011 and CAR-T in 2017 a wave of new approaches has ...
By Lisa ThompsonOTC:NEXCFREAD THE FULL NEXCF RESEARCH REPORTToday, NexTech (OTC:NEXCF) reported the FYQ1 2020 quarter that ended August 31, 2019. Revenues and earnings were on target with our forecasts. Revenues were $1.5 million and EPS was a loss o ...
By David Bautz, PhDNASDAQ:MNOVREAD THE FULL MNOV RESEARCH REPORT HERE Business Update Phase 3 Trial of MN-166 in ALS Underway In April 2019, MediciNova, Inc. (NASDAQ:MNOV) announced that following review of the protocol the U.S. Food and Drug A ...
By David Bautz, PhDNASDAQ:BTAI READ THE FULL BTAI INITIATION REPORT HERE Initiating Coverage We are initiating coverage of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) with a valuation of $21.00. BioXcel Therapeutics is a biopharmaceutical company utiliz ...
By David Bautz, PhDTSX:MDNA.TO READ THE FULL MDNA.TO RESEARCH REPORT Financial Update On October 17, 2019, Medicenna Therapeutics Corp. (TSX:MDNA.TO) announced the closing of a previously announced public offering in which the company issued a total ...
NASDAQ:BLPH Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) is a clinical development-stage medical therapeutics company focused on the development and commercialization of INOpulse, a novel nitric oxide therapy which, if successfully developed and appr ...
By Brian Marckx, CFANASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT When Aethlon Medical (NASDAQ:AEMD) reported fiscal Q1 2020 financial results in August, management noted that they anticipated imminent filing of an Investigational Device Exemption ( ...
By John VandermostenOTC:PMN.TO | OTC:ARFXF Seven months ago, Biogen (NASDAQ:BIIB) shocked the neurodegenerative disease community announcing that they would discontinue their two Phase III aducanumab trials for Alzheimer’s Disease (AD). The Independe ...
12346220 / 619 POSTS